Halozyme Therapeutics is searching for cures to the world's "ologys." The company is developing treatments for endocrinology, oncology, and dermatology. It is also creating products for the drug delivery market. Halozyme's portfolio is based on its Enhanze technology which includes the family of human enzymes called hyaluronidases. There are two marketed products using Halozyme's technology: Hylenex and Cumulase. Hylenex is used as an adjuvant for drug and fluid infusions and Cumulase is used for in-vitro fertilization. Halozyme receives limited income from sales of the active pharmaceutical ingredients to the third party that makes Cumulase, as well as revenues from its partnerships with ViroPharma and Roche.